Breaking News Instant updates and real-time market news.

EVHC

Envision Healthcare

$38.23

0.44 (1.16%)

, KKR

KKR

$20.13

0.12 (0.60%)

09:56
04/09/18
04/09
09:56
04/09/18
09:56

Five suitors said to eye Envision as presentations wrap up, Dealreporter says

Envision Healthcare (EVHC), which is understood to have wrapped up management presentations for suitors, is said to be pursued by five groups - KKR (KKR); Blackstone (BX) portfolio company Team Health; CVC Capital paired with Leonard Green; a Hellman & Friedman, Onex and Clayton Dubilier & Rice consortium; and Carlyle Group (CG) partnering with TPG - said Dealreporter, according to contacts.

EVHC

Envision Healthcare

$38.23

0.44 (1.16%)

KKR

KKR

$20.13

0.12 (0.60%)

BX

Blackstone

CG

Carlyle Group

$20.25

-0.65 (-3.11%)

  • 11

    Apr

  • 12

    Apr

  • 19

    Apr

EVHC Envision Healthcare
$38.23

0.44 (1.16%)

03/15/18
JEFF
03/15/18
NO CHANGE
Target $46
JEFF
Buy
Envision selloff yesterday a buying opportunity, says Jefferies
Jefferies analyst Brian Tanquilut views yesterday's selloff in shares of Envision Healthcare (EVHC) following news that UnitedHealth (UNH) dropped out of the bidding process for the company's ASC segment as an overreaction. The analyst continues to believe that the board's strategic review will result in a sale of Envision. He believes yesterday's pullback provides a "compelling entry opportunity." His leveraged buyout analysis says a $50-plus per share takeout is possible. Tanquilut keeps a Buy rating on Envision Healthcare with a $46 price target.
03/07/18
JPMS
03/07/18
NO CHANGE
JPMS
Overweight
Envision leveraged buyout in $40-$50 range still plausible, says JPMorgan
JPMorgan analyst Gary Taylor continue to believe a leveraged buyout of Envision Healthcare (EVHC) in the $40-$50 per share range is plausible. UnitedHealth's (UNH) reported interest in Envision's ambulatory surgery segment is a "potential positive catalyst," Taylor tells investors in a research note. He says this could skew his thinking towards the upper half of the estimated LBO range. The analyst keeps an Overweight rating on Envision shares.
03/07/18
BARD
03/07/18
NO CHANGE
Target $50
BARD
Outperform
Envision Healthcare price target raised to $50 from $45 at Baird
Baird analyst Whit Mayo raised his price target on Envision Healthcare to $50 from $45 as he continues to believe the company will be sold and he believes investors have materially under-estimated the chances of strategic bidders engaging in the sales process. He believes a sale north of $50 is doable. Mayo reiterated his Outperform rating on Envision Healthcare shares.
03/01/18
RHCO
03/01/18
NO CHANGE
Target $45
RHCO
Buy
Envision Healthcare price target raised to $45 from $40 at SunTrust
SunTrust analyst David MacDonald raised his price target on Envision Healthcare to $45, saying the Q4 earnings call was upbeat with a focus on positive underlying trends, operational improvements, and FY18 expectations of transitioning its book of business to in-network. MacDonald keeps his Buy rating on SunTrust.
KKR KKR
$20.13

0.12 (0.60%)

11/28/17
SDLR
11/28/17
INITIATION
Target $21
SDLR
Hold
KKR resumed with a Hold at Sandler ONeill
Sandler O'Neill resumed coverage of KKR with a Hold rating and $21 price target.
01/09/18
GSCO
01/09/18
UPGRADE
Target $29
GSCO
Conviction Buy
KKR upgraded to Conviction Buy from Buy at Goldman Sachs
Goldman Sachs analyst Alexander Blostein upgraded KKR to Conviction Buy and raised his price target for the shares to $29 from $24.50. The analyst sees the "evolution of KKR's business mix" leading to a more stable earnings profile and higher multiple over time. KKR remains the most inexpensive stock among alternative managers, Blostein tells investors in a research note.
01/10/18
FBCO
01/10/18
NO CHANGE
Target $31
FBCO
Outperform
KKR price target raised to $31 from $23 at Credit Suisse
Credit Suisse analyst Craig Siegenthaler raised his price target for KKR to $31 from $23 as he believes the macro backdrop should provide tailwinds for the Alternative Asset Managers while lower corporate tax rate should boost the valuation of their underlying portfolios. The analyst reiterates an Outperform rating on the shares.
01/30/18
MSCO
01/30/18
NO CHANGE
MSCO
Morgan Stanley says Ares may be first, Apollo may gain most from C-corp convert
Morgan Stanley analyst Michael Cyprys said he sees an opportunity for Alternative Asset Managers to unlock value by converting to C-corps, as shifting from a partnership structure could help alleviate some tax reporting complexities and expand the universe of eligible investors. He sees Ares Management (ARES) as possibly the first to convert and expects a potential announcement or indications of management's intentions about a conversion when the company reports earnings on February 15. While Ares may be first, Cyprys sees Apollo Global (APO) as potentially being able to unlock the most value from a conversion, with 26% near-term upside possible if the shares re-rate. He sees a less favorable conversion scenario for asset managers with lower taxes and/or greater exposure to performance fees, including KKR (KKR), Carlyle Group (CG) and Blackstone (BX), Cyprys tells investors.
BX Blackstone

01/31/18
MSCO
01/31/18
NO CHANGE
Target $40
MSCO
Overweight
Blackstone could be next disruptor, says Morgan Stanley
Following Blackstone's (BX) purchase of a 55% stake in Thomson Reuters' Financial and Risk business, Morgan Stanley analyst Michael Cyprys said Blackstone's deal signals the growing value in data and he sees opportunities for the asset manager to enhance its tool kit with big data and AI in order to bring transformational change to companies and industries. With nearly $100B in dry powder on which leverage can be applied, suggesting well over half trillion in spending power, Cyprys sees potential for Blackstone to act as a disruptor, he tells investors. The analyst keeps an Overweight rating and $40 price target on Blackstone shares.
03/20/18
DBAB
03/20/18
NO CHANGE
Target $126
DBAB
Buy
Celanese joint venture termination disappointing, says Deutsche Bank
Deutsche Bank analyst David Begleiter says the termination of Celanese's (CE) proposed acetate tow joint venture with Blackstone (BX) is disappointing, but not surprising. The odds of the combination being approved have been falling since October when the European Commission announced it had opened an in-depth investigation, Begleiter tells investors in a research note. The analyst lowered his price target for Celanese to $126 from $130 and keeps a Buy rating on the shares.
03/20/18
BARD
03/20/18
NO CHANGE
Target $130
BARD
Outperform
Baird reiterates Outperform rating on Celanese after tow JV terminated
Baird analyst Ghansham Panjabi reiterated his Outperform rating on Celanese (CE) following news that the company's joint venture with Blackstone's (BX) Rhodia Acetow business was terminated. In a research note to investors, Panjabi said that while the tow JV termination is "disappointing" and could weigh on shares, his long-term thesis is intact, as this outcome is "not overly surprising" given the extended timeline of the regulatory approvals process with the European Commission. He believes Celanese's management will remain "active" in its efforts to optimize the portfolio. The analyst has a $130 price target on shares.
03/27/18
RAJA
03/27/18
INITIATION
RAJA
Market Perform
Blackstone initiated with a Market Perform at Raymond James
CG Carlyle Group
$20.25

-0.65 (-3.11%)

02/14/18
JEFF
02/14/18
UPGRADE
Target $27
JEFF
Buy
Carlyle Group upgraded to Buy from Hold at Jefferies
Jefferies analyst Gerald E. O'Hara upgraded Carlyle Group to Buy and raised his price target for the shares to $27 from $23. The analyst sees an attractive entry point for the shares with the company at the midway point of a $100B fundraising cycle. He believes Carlyle's net accrued performance fees are poised for continued growth with all main drawdown funds currently in carry contribution.
03/12/18
SBSH
03/12/18
UPGRADE
Target $28.5
SBSH
Buy
Carlyle Group upgraded to Buy from Neutral at Citi
Citi analyst William Katz upgraded Carlyle Group to Buy and raised his price target for the shares to $28.50 from $25. The analyst sees a higher FRE outlook and believes the recent pullback in shares enhances the risk adjusted return.
03/12/18
03/12/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Time Warner (TWX) upgraded to Buy from Neutral at UBS with analyst John Hodulik saying while he expects the takeover by AT&T (T) to receive regulatory approval, he believes the current environment would make Time Warner's assets "highly attractive" to other media companies and Internet-based competitors were the deal to be blocked. 2. Carlyle Group (CG) and Apollo Global (APO) were upgraded to Buy from Neutral at Citi. 3. Merck (MRK) upgraded to Outperform from Market Perform at Leerink with analyst Seamus Fernandez saying Keytruda will continue to dominate the first-line non-small cell lung cancer market. 4. SAP (SAP) upgraded to Outperform from In Line at Evercore ISI with analyst Stewart Materne III saying that he believes the risk/reward is more attractive at current levels following the stock's 6% pullback. 5. Aratana Therapeutics (PETX) upgraded to Buy on valuation at CL King with the firm citing favorable risk/reward. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
03/27/18
SBSH
03/27/18
NO CHANGE
SBSH
Citi says AkzoNobel free to think more strategically about M&A after divestiture
After AkzoNobel (AKZOY) announced the sale of its Specialty Chemicals business to Carlyle Group (CG) and GIC, Citi analyst P.J. Juvekar said the divestiture frees up the company to think more strategically about M&A. Akzo could go after Axalta (AXTA) again, but unless Akzo is prepared to pay a significant premium a deal is unlikely, said Juvekar. He thinks a price in the mid to high $30 range would be needed to get Axalta to the negotiating table. Akzo has thus far resisted a sale to PPG (PPG), but Juvekar thinks PPG would be interested if a deal were to be a friendly one.

TODAY'S FREE FLY STORIES

RHHBY

Roche

05:30
04/23/18
04/23
05:30
04/23/18
05:30
Hot Stocks
Genentech says 4 years of continuous Ocrevus treatment reduces RMS activity »

Genentech, a member of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 21

    May

  • 30

    May

UBS

UBS

$17.66

-0.005 (-0.03%)

05:27
04/23/18
04/23
05:27
04/23/18
05:27
Earnings
UBS reports Q1 EPS CHF 0.39 vs. CHF 0.33 last year »

Reports Q1 profit before…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

  • 23

    May

BHVN

Biohaven Pharmaceutical

$27.19

-0.07 (-0.26%)

05:21
04/23/18
04/23
05:21
04/23/18
05:21
Hot Stocks
Biohaven announces key secondary outcome measures from rimegepant Phase 3 trials »

Biohaven Pharmaceutical…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

  • 12

    Jun

OPBK

OP Bancorp

05:12
04/23/18
04/23
05:12
04/23/18
05:12
Initiation
OP Bancorp initiated  »

OP Bancorp initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MRK

Merck

$58.82

0.18 (0.31%)

05:11
04/23/18
04/23
05:11
04/23/18
05:11
Upgrade
Merck rating change  »

Merck upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

  • 24

    Apr

  • 27

    Apr

  • 01

    May

  • 08

    May

  • 05

    Jun

  • 23

    Oct

BDORY

Banco do Brasil

05:04
04/23/18
04/23
05:04
04/23/18
05:04
Downgrade
Banco do Brasil rating change  »

Banco do Brasil…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

STT

State Street

$99.64

-4.57 (-4.39%)

05:02
04/23/18
04/23
05:02
04/23/18
05:02
Upgrade
State Street rating change  »

State Street upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 26

    Apr

KORS

Michael Kors

$65.02

-0.7 (-1.07%)

04:57
04/23/18
04/23
04:57
04/23/18
04:57
Upgrade
Michael Kors rating change  »

Deutsche Bank upgrades…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SYRS

Syros Pharmaceuticals

$12.60

-0.47 (-3.60%)

04:55
04/23/18
04/23
04:55
04/23/18
04:55
Conference/Events
Syros Pharmaceuticals management to meet with Oppenheimer »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

  • 24

    May

AVEO

Aveo Oncology

$2.59

-0.05 (-1.89%)

04:55
04/23/18
04/23
04:55
04/23/18
04:55
Conference/Events
Aveo Oncology management to meet with B. Riley FBR »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

  • 24

    Apr

KMB

Kimberly-Clark

$100.04

-3.3 (-3.19%)

04:55
04/23/18
04/23
04:55
04/23/18
04:55
Technical Analysis
Technical Earnings Preview: Kimberly-Clark near 5-year lows ahead of earnings »

The shares of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

  • 27

    Apr

  • 30

    May

INFY

Infosys

$17.38

0.21 (1.22%)

04:55
04/23/18
04/23
04:55
04/23/18
04:55
Conference/Events
Infosys to host analyst meeting »

Analyst meeting to be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

CIGI

Colliers International

$70.20

0.75 (1.08%)

04:55
04/23/18
04/23
04:55
04/23/18
04:55
Conference/Events
UBS REITs analyst to hold an analyst/industry conference call »

REITs Analyst Yulico,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

  • 30

    Apr

  • 01

    May

CNAT

Conatus

$3.58

0.02 (0.56%)

04:55
04/23/18
04/23
04:55
04/23/18
04:55
Conference/Events
Conatus management to meet with Oppenheimer »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

  • 24

    Apr

04:55
04/23/18
04/23
04:55
04/23/18
04:55
General news
Existing Home Sales to be reported at 10:00 »

March Existing Home Sales…

04:55
04/23/18
04/23
04:55
04/23/18
04:55
General news
Breaking General news story  »

6-Month Bill Auction to…

MLNX

Mellanox

$75.80

-1.45 (-1.88%)

04:55
04/23/18
04/23
04:55
04/23/18
04:55
Conference/Events
Mellanox management to meet with Loop Capital »

Meeting to be held in Los…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

  • 24

    Apr

APVO

Aptevo Therapeutics

$4.33

0.01 (0.23%)

04:55
04/23/18
04/23
04:55
04/23/18
04:55
Conference/Events
Aptevo Therapeutics management to meet with Piper Jaffray »

Meetings to be held on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

  • 24

    Apr

04:55
04/23/18
04/23
04:55
04/23/18
04:55
General news
PMI Composite Flash â€' Level to be reported at 09:45 »

April PMI Composite Flash…

04:55
04/23/18
04/23
04:55
04/23/18
04:55
General news
Breaking General news story  »

4-Week Bill Announcement…

IFRX

InflaRx

$38.78

1.67 (4.50%)

04:55
04/23/18
04/23
04:55
04/23/18
04:55
Conference/Events
InflaRx has a conference call hosted by JPMorgan »

JPMorgan Analyst Rama…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

04:55
04/23/18
04/23
04:55
04/23/18
04:55
Conference/Events
Leerink healthcare analysts to hold an analyst/industry conference call »

Analysts discuss dental…

LUK

Leucadia

$24.02

-0.1 (-0.41%)

04:55
04/23/18
04/23
04:55
04/23/18
04:55
Conference/Events
Leucadia management to meet with Oppenheimer »

Group luncheon to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

  • 23

    May

  • 04

    Oct

CNK

Cinemark

$39.66

-0.74 (-1.83%)

04:55
04/23/18
04/23
04:55
04/23/18
04:55
Conference/Events
Cinemark management to meet with MKM Partners »

Meeting to be held in Las…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

  • 23

    Apr

  • 24

    Apr

  • 25

    Apr

CRAY

Cray

$22.40

-0.2 (-0.88%)

04:55
04/23/18
04/23
04:55
04/23/18
04:55
Conference/Events
Cray management to meet with Craig Hallum »

Meeting to be held in Los…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

  • 29

    May

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.